Cargando…

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jin, Jiang, Hongchuan, Zhang, Jian, Bao, Guoqiang, Zhang, Guoqiang, Wang, Haibo, Wang, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650529/ https://www.ncbi.nlm.nih.gov/pubmed/34872507 http://dx.doi.org/10.1186/s12885-021-09050-6

Ejemplares similares

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
por: Hu, Wenxian, et al.
Publicado: (2021)

Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
por: Dong, Minjun, et al.
Publicado: (2018)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin
por: Liu, Weifang, et al.
Publicado: (2021)

Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis
por: Wang, Li, et al.
Publicado: (2020)

The effect of monosialylganglioside mix modifying the PEGylated liposomal epirubicin on the accelerated blood clearance phenomenon
por: Zhang, Ting, et al.
Publicado: (2017)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
por: Hung, Chih-Chiang, et al.
Publicado: (2020)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)
por: Li, Ruoyang, et al.
Publicado: (2019)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
por: Li, Xin-Ru, et al.
Publicado: (2022)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy
por: Yang, Qiang, et al.
Publicado: (2013)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2–3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells
por: Juang, Vivian, et al.
Publicado: (2016)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma
por: Wei, Minyan, et al.
Publicado: (2015)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
por: Wang, Haoqi, et al.
Publicado: (2022)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
por: Eckes, Jürgen, et al.
Publicado: (2011)

Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study
por: Zhang, Mengmeng, et al.
Publicado: (2020)

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
por: Vici, Patrizia, et al.
Publicado: (2011)

Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2019)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients
por: URAKAWA, HIROSHI, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hp0r8nkmjlt6p2cle9qgs9pq80